Protein engineering market is set for steady growth to reach US$ 8,646.10 Million by 2033, strong CAGR of 15.6% | Key Players:- Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., Bio-Rad Laboratories.

The global protein engineering market reached US$ 2,854.54 Million in 2024 and is expected to reach US$ 8,646.10 Million by 2033, growing at a CAGR of 15.6 % during the forecast period of 2025-2033.

DataM Intelligence unveils its latest report on the "protein engineering market size 2026," offering an in-depth analysis of market trends, growth drivers, competitive landscape, and regional dynamics. The study covers market size in value and volume, CAGR forecasts, and emerging opportunities that can guide businesses in seizing growth potential and crafting winning strategies. Packed with data-driven insights on current developments and future trends, this report is essential for companies aiming to stay ahead in the competitive Market.

Download a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/protein-engineering-market?pratik

United States: Key Industry Developments
✅ November 2025: Amgen partnered with Generate Biomedicines to advance AI-powered protein engineering platforms for developing next-generation biologics, accelerating therapeutic antibody design and optimization for oncology and immunology applications.
​
✅ October 2025: Future Fields opened Instar 1.0 biomanufacturing facility in the U.S., leveraging precision fermentation for scalable production of engineered proteins targeting chronic diseases like diabetes and cancer.
​
✅ September 2025: FDA streamlined approvals for AI-driven protein therapeutics, boosting U.S. biotech investments in engineered enzymes and monoclonal antibodies amid rising demand from 129 million chronic disease patients.
​
Asia Pacific / Japan: Key Industry Developments
✅ November 2025: Japanese biotech firms increased R&D funding for protein engineering in synthetic biology, focusing on industrial enzymes for biofuels and sustainable agriculture to support precision fermentation advancements.
​
✅ October 2025: Takeda Pharmaceutical collaborated on protein-engineered vaccines using structure-based design, enhancing antiviral properties for metabolic disorders prevalent in aging Asian populations.
​
✅ August 2025: Government subsidies in Japan promoted protein engineering for biopharmaceuticals, integrating AI tools to improve monoclonal antibody yields and commercialization in healthcare protocols.

M&A Activity
Thermo Fisher Scientific acquired Ingenza, a UK-based protein engineering firm, in January 2025 to bolster synthetic biology and enzyme capabilities for biomanufacturing. Fortifi acquired Les Innovations Mecaniques Alimentaires in July 2024, enhancing protein processing equipment for food applications.​​

Partnerships
Codexis partnered with Thermo Fisher Scientific in May 2025 to co-develop next-generation protein therapeutics using enzyme engineering and biomanufacturing expertise. Navigo Proteins collaborated with Oncodesign Precision Medicine in March 2024 on Affilins® for radiotherapy agents.​

Product Developments
Integration of AI across protein design, high-throughput screening, and CRISPR tools accelerates novel protein therapeutics and diagnostics. Emerging sustainable solutions and precision medicine platforms target chronic diseases like diabetes

Competitive Landscape
The major global players in the protein engineering market include Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Bruker Corporation, Genscript Biotech Corporation, Codexis, Inc., Waters Corporation, New England Biolabs, Inc., Merck KGaA, PerkinElmer, Inc., Danaher Corp. (Cytiva), and Amgen, Inc., among others.

Growth Drivers
◾ Biopharma R&D Surge: Pharma/biotech firms ramp up protein therapeutics for cancer, autoimmune diseases, and gene therapies, offering superior efficacy over small molecules; COVID-19 accelerated vaccine/diagnostic applications.

◾ Tech Advancements: AI/ML (deep learning, neural networks) and rational design enable precise protein modification; directed evolution boosts novel structures for drugs/enzymes.
​
◾ Targeted Therapy Demand: Rising chronic disease prevalence drives engineered antibodies, enzymes for oncology/immunology; better patient outcomes fuel adoption.

📌 Buy Now & Unlock 360° Market Intelligence:https://www.datamintelligence.com/buy-now-page?report=protein-engineering-market?pratik

Regional Highlights

North America dominates the global protein engineering market, capturing around 38% share through 2035 due to robust R&D investments, established CROs, and biotech hubs driving innovations like AI-based protein design and CRISPR applications.

Asia-Pacific exhibits the fastest growth at a projected CAGR of 15%, fueled by rising biotech startups, government funding for genomics/proteomics, and expanding biomanufacturing in countries like China, India, and Japan

Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/protein-engineering-market?pratik

Market Segmentation:-

The Global Protein Engineering Market features detailed segmentation across product types, protein types, technologies, and end-users, reflecting diverse applications in biopharmaceutical development and research. Each segment contributes uniquely to market dynamics, with specific shares derived from recent industry analyses.

Product Type
Consumables, including reagents and kits, dominate due to high recurring demand in protein modification workflows, holding 52.5% market share in 2024. Instruments, such as mass spectrometers and chromatography systems, follow with around 30% share from their role in precise analysis despite higher costs. Software & Services capture the remaining 17.5% share, growing fastest via AI integration for design optimization.
​
Protein Type
Monoclonal Antibodies lead with over 38% share as the largest segment, driven by oncology and immunotherapy demands. Insulin follows at approximately 15% share from diabetes management innovations. Erythropoietins, Vaccines, Interferons, Coagulation Factors, Colony-Stimulating Factors, and Growth Hormones collectively hold the rest, with vaccines at 12% amid pandemic responses

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele

This release was published on openPR.